CRP and bone inflammation disease: DCE-MRI Ktrans and RAMRIS synovitis and osteitis showed stable disease activity with placebo treatment, and each measure had a treatment effect size with infliximab that was quantitatively similar to the DAS28(CRP) benchmark.